What the published research says about sermorelin
A short, honest summary of where the sermorelin evidence is strong, where it is thin, and what that means for someone considering it.
TL;DR
- Sermorelin's strongest research base is pediatric — the Geref trials that earned its 1990 FDA approval for childhood growth hormone deficiency.
- Adult off-label data describes IGF-1 increases, improved deep-sleep markers, and a generally well-tolerated profile, but most studies are small.
- There are no large modern randomized trials in healthy adults, which is why a clinician evaluation matters.
What it is
Sermorelin is a 29-amino-acid peptide (in plain English: a short chain of building blocks) that prompts the pituitary gland to release a pulse of growth hormone. The published research splits into two eras: the pediatric trials that supported the original FDA approval as Geref, and a smaller body of adult off-label work that runs from the 1990s to today.
How it works
Sermorelin binds the GHRH receptor (in plain English: the docking site that triggers natural GH release). Studies measured what happened next — IGF-1 going up over weeks, deeper slow-wave sleep on EEG, and modest body-composition shifts in some cohorts. Picture a thermostat that nudges the body's GH dial back toward a younger pulse pattern. The research mostly tracks downstream signals like IGF-1, not direct outcomes (PubMed sermorelin records).
Who asks about it
People come to this topic when a clinician has proposed sermorelin and they want the receipts — actual studies, real journals, honest limits. Many are also comparing what's known about sermorelin to what's known about CJC-1295 or testosterone replacement.
What the research says
The pediatric Geref trials reported meaningful growth-velocity gains and mild side effects (FDA Drugs@FDA — Geref record). Adult work is thinner. Smaller studies and physician case series describe IGF-1 rises in the range of 30–80 ng/mL over 12–16 weeks (about a quarter to a half of typical baseline), better measured deep-sleep time, and reductions in fasting glucose excursions in some — not all — cohorts. Side effects in those reports were mild and infrequent: injection-site irritation, occasional flushing, mild headache in fewer than 1 in 10 patients.
What to know before considering it
The honest summary: sermorelin's pediatric record is solid; the adult record is suggestive, not definitive. That is not unusual for off-label peptides — but it does mean a clinician should set realistic expectations, order baseline IGF-1 labs, and recheck after 12 weeks. The compounded version is not FDA-approved as a finished drug.
The Halftime POV
Sermorelin is one of the most-studied peptides in our category — and most of its evidence is decades old and pediatric. That's a useful frame: the biology is well-understood, the adult outcome data is still being written, and a careful clinician-led protocol is how the gap gets bridged responsibly.
Related reading:
- Sermorelin explained: the GHRH analog primer
- How sermorelin signals growth hormone release
- Sermorelin side effects: what the literature reports
- Sermorelin regulatory status and compounding access in 2026
FAQ
Q: Is sermorelin backed by clinical research? A: Yes. Sermorelin was studied in pediatric growth-hormone-deficiency trials that supported its 1990 FDA approval as Geref. A separate body of adult off-label literature describes IGF-1 response, sleep effects, and a generally well-tolerated profile.
Q: What did the pediatric sermorelin studies show? A: Children with documented GH deficiency showed measurable growth velocity gains over 6–12 months on daily sermorelin, with side effects mostly limited to mild injection-site reactions.
Q: Are there large adult sermorelin trials? A: Adult use is mostly off-label. The published adult literature includes smaller cohort studies and physician case series, not large randomized trials. That gap is one reason sermorelin is prescribed under licensed clinician evaluation, not over-the-counter.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is sermorelin backed by clinical research?
Yes. Sermorelin was studied in pediatric growth-hormone-deficiency trials that supported its 1990 FDA approval as Geref. A separate body of adult off-label literature describes IGF-1 response, sleep effects, and a generally well-tolerated profile.
What did the pediatric sermorelin studies show?
Children with documented GH deficiency showed measurable growth velocity gains over 6–12 months on daily sermorelin, with side effects mostly limited to mild injection-site reactions.
Are there large adult sermorelin trials?
Adult use is mostly off-label. The published adult literature includes smaller cohort studies and physician case series, not large randomized trials. That gap is one reason sermorelin is prescribed under licensed clinician evaluation, not over-the-counter.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.